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The synthetic steroid mifepristone blocks the growth of ovarian cancer cells, yet the mech-
anism driving such effect is not entirely understood. Unbiased genomic and proteomic
screenings using ovarian cancer cell lines of different genetic backgrounds and sensitiv-
ities to platinum led to the identification of two key genes upregulated by mifepristone
and involved in the unfolded protein response (UPR): the master chaperone of the endo-
plasmic reticulum (ER), glucose regulated protein (GRP) of 78 kDa, and the CCAAT/
enhancer binding protein homologous transcription factor (CHOP). GRP78 and CHOP
were upregulated by mifepristone in ovarian cancer cells regardless of p53 status and plat-
inum sensitivity. Further studies revealed that the three UPR-associated pathways, PERK,
IRE1a, and ATF6, were activated by mifepristone. Also, the synthetic steroid acutely
increased mRNA translation rate, which, if prevented, abrogated the splicing of XBP1
mRNA, a non-translatable readout of IRE1a activation. Moreover, mifepristone increased
LC3-II levels due to increased autophagic flux. When the autophagicelysosomal pathway
was inhibited with chloroquine, mifepristone was lethal to the cells. Lastly, doses of pro-
teasome inhibitors that are inadequate to block the activity of the proteasomes, caused
cell death when combined with mifepristone; this phenotype was accompanied by accu-
mulation of poly-ubiquitinated proteins denoting proteasome inhibition. The stimulation(C.M. Telleria).
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lizing this compound to sensitize ovarian cancer cells to proteasome or lysosome
inhibitors.
ª 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction and retro-translocated to the cytoplasm where they are ubiq-The lethality of ovarian cancer can be attributed to its late
diagnosis and a lack of long-term effective treatment ap-
proaches. Since the introduction of debulking surgery and
platinumetaxane combination therapy over 30 years ago,
there has been no significant breakthrough impacting the
overall survival of ovarian cancer patients. Although over
70% of diagnosed women respond to front-line standard of
care with remission, the disease hides as microscopic or min-
imal residual within the abdominal cavity for about 18e24
months, recurring thereafter with a phenotype usually not
responsive to current chemotherapeutic agents (Bast, 2011;
Bast et al., 2009; Coleman et al., 2013; Kurman and Shih Ie,
2011; Romero and Bast, 2012; Vaughan et al., 2011). Because
patients are left without treatment between remission and
recurrence, it is imperative to develop consolidation therapies
that can be used chronically after standard of care. We previ-
ously reported that mifepristone and other antiprogestins are
potential candidates to achieve such a goal (Goyeneche and
Telleria, 2015; Telleria and Goyeneche, 2012) as they: (i) block
growth of ovarian cancer cells in vitro and in vivo
(Goyeneche et al., 2007); (ii) arrest ovarian cancer cells at the
G1 phase of the cell cycle by increasing the abundance of
Cdk inhibitors p21cip1 and p27kip1, and inhibiting the activity
of cyclin dependent kinase 2 (Cdk2) (Goyeneche et al., 2012);
(iii) do not require progesterone receptors to block cell growth
(Tieszen et al., 2011); (iv) prevent the repopulation of ovarian
cancer cells following cytotoxic chemotherapy with cisplatin
(Freeburg et al., 2009b) or cisplatin plus paclitaxel (Gamarra-
Luques et al., 2012); (v) synergize with inhibitors of the PI3K/
Akt survival pathway killing ovarian cancer cells (Wempe
et al., 2013); and (vi) growth-arrest ovarian cancer cells that
are sensitive or resistant to cisplatin and/or paclitaxel
(Freeburg et al., 2009a; Gamarra-Luques et al., 2014).
Using unbiased genomic and proteomic approaches to
shed light on the signaling evoked by mifepristone as an
anti-ovarian cancer agent, we discovered in the present
work thatmifepristone induces the unfolded protein response
(UPR) and increases autophagic flux in ovarian cancer cells.
The UPR represents a series of signaling transduction events
that ameliorate the accumulation of unfolded/misfolded pro-
teins caused by loss of homeostasis in the endoplasmic retic-
ulum (ER) (a.k.a. ER stress) (Gardner et al., 2013; Hetz, 2012; Luo
and Lee, 2013; Rutkowski and Kaufman, 2007; Sano and Reed,
2013; Schonthal, 2013; Verfaillie et al., 2013). The UPR pro-
motes protein folding by increasing expression of resident
ER chaperones, transiently blocking global protein synthesis,
and enhancing ER assisted degradation (ERAD) (Sano and
Reed, 2013). During ERAD, misfolded proteins are recognizeduitinated and targeted for proteasome degradation (Brodsky,
2012; Lederkremer, 2009; Needham and Brodsky, 2013;
Vembar and Brodsky, 2008). When ER stress is acute, the
corrective measures induced by the UPR allows for cell sur-
vival; conversely, when the stress is chronic and the load of
unfolded/misfolded proteins critically exceeds the homeo-
static capacity of the ER, the UPR triggers cell death (Hetz,
2012; Logue et al., 2013; Sano and Reed, 2013; Urra et al.,
2013; Verfaillie et al., 2013). In cases where excess accumula-
tion of unfolded proteins leads to protein aggregation, the
amelioration of ER stress and restoration of the protein folding
environment of the ER is further achieved by the activation of
autophagy (Nagelkerke et al., 2014; Wang and Terpstra, 2013).
Herein, we prove that mifepristone triggers the UPR as a
consequence of increased protein synthesis. Secondly, we
show that mifepristone increases autophagic flux and kills
ovarian cancer cells in combinationwith a lysosome inhibitor.
Lastly, we demonstrate that if mifepristone is associated with
a proteasome inhibitor that interferes with ERAD, thus not
allowing the cells to degrade misfolded/unfolded proteins
via the ubiquitin proteasome system (UPS), the cells die.2. Materials and methods
2.1. Cell lines and in vitro exposure of the cells to drugs
The human carcinoma cell line OV2008 and its platinum-
resistant sibling OV2008/C13 were obtained from Dr. Stephen
Howell (University of California, San Diego) and were main-
tained in RPMI-1640 (Mediatech, Herndon, VA) supplemented
with 5% heat inactivated fetal bovine serum (Atlanta Biologi-
cals, Lawrenceville, GA) and 10 mM HEPES (Mediatech),
4 mM L-glutamine (Mediatech), 1 mM sodium pyruvate (Medi-
atech), 100 IU penicillin (Mediatech), and 100 mg/ml strepto-
mycin (Mediatech). The SKOV-3 cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and
were cultured in RPMI-1640 (Mediatech) with 5% fetal bovine
serum (Atlanta Biologicals), 10 mM HEPES (Mediatech), 4 mM
L-glutamine (Mediatech), 0.45% D (þ) glucose (Sigma Chemical
Co., St. Louis, MO), 1 mM sodium pyruvate (Mediatech), 1
non-essential amino acids (Mediatech), 100 IU penicillin
(Mediatech), 100 mg/ml streptomycin (Mediatech), and
0.01 mg/ml human insulin (Roche, Indianapolis, IN). All cells
weremaintained at 37 C in a humidified atmosphere contain-
ing 95% air/5%CO2. The drugs used to treat the cells were vehi-
culized in DMSO, and the maximal concentration of DMSO in
the culture media was 0.2% (v/v). The providers of the drugs
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Life Sciences, Farmingdale, NY); bortezomib (Millennium
Pharmaceuticals, Cambridge, MA); chloroquine (Sigma); salu-
brinal (EMD Millipore, Billerica, MA); cycloheximide (Sigma).
2.2. Cell proliferation and viability
Following different treatment approaches, the number of cells
as well as their viability was assessed via microcapillary fluo-
rescence cytometry as we previously reported in detail
(Freeburg et al., 2009b).
2.3. Deoxyribonucleic acid microarray
Total RNA was extracted in TRI reagent with a Polytron ho-
mogenizer. After centrifugation, the aqueous layer containing
total RNA was removed, mixed with RLT buffer (Qiagen,
Valencia, CA) and ethanol, and centrifuged through a Qiagen
RNeasy column. The column was washed, and the sample
was treated with ribonuclease-free deoxyribonuclease (Qia-
gen) to remove residual DNA. Total RNA was eluted from the
column using nuclease free water. The quality and quantity
of RNA were assessed using the RNA 6000 Nano LabChip in
an Agilent Bioanalyzer (Agilent Technologies, Santa Clara,
CA).
The Codelink Whole Human Genome Bioarray (Applied
Microarrays, Tempe, AZ) was used for the DNA microarray
analysis of gene expression. These microarrays contain
w53,000 single stranded 30-mer oligonucleotide probes for
human genes/transcribed sequences. Sample processing and
hybridization into DNA microarrays was carried out as previ-
ously described (Eyster and Brannian, 2009) using 1 mg total
RNA as startingmaterial. The slides were scannedwith a Gen-
ePix 4000B scanner (Molecular Devices, Sunnyvale, CA) and
analyzed with GenePix Pro (Molecular Devices), CodeLink
(Applied Microarrays), Acuity (Molecular Devices), and Gene-
Spring 7.0 (Agilent) software. The GenePix Pro software
aligned and acquired themicroarray image. Codelink software
5.0 was used to apply the background correction. Fold expres-
sion values were obtained from analysis by using the Acuity
software. GeneSpring software was used to normalize the
expression of each gene to the median gene expression and
each slide to the 50th percentile of gene expression, and for
statistical analysis of the microarray data. The complete
data for these microarrays is available at the NCBI Gene
Expression Omnibus (www.ncbi:nlm.nih.gov/geo) and can be
accessed through GEO accession number GSE29763.
2.4. Class comparison and pathway analyses
The microarray data generated using the Codelink Whole Hu-
man Genome Bioarray using OV2008 and OV2008/C13 cells
were imported into BRB Arraytools, log2-transformed, and
quantile normalized. Probe intensities <10 were thresholded,
and exclusion filters (<20% of probe values have at least a 1.5-
fold change in either direction from the probe’s median value
or>50%missing data) was applied. Out of 53,079 probe values,
1927 passed the filter. The resulting probe values were sub-
jected to class comparison analysis limited to each cell line.
The significantly affected genes were subjected to IngenuityPathway Analysis (IPA) as previously described (Roy et al.,
2014).
A building pathway flow searching database was addition-
ally performed using Pathway Studio (Elsevier Inc.) and a
mammalian dataset (ResNet 2.5 database). The hypothetical
pathways affected by mifepristone in ovarian cancer cells
were built based on genes we previously discovered to be
regulated by the synthetic steroid following hypothesis-
driven experiments (Goyeneche et al., 2007; Tieszen et al.,
2011; Wempe et al., 2013) in combination with themost repre-
sentative genes significantly regulated by mifepristone and
discovered in the present study via unbiased genomic and
proteomic platforms.
2.5. Real time RT-PCR
Real time RT-PCR was performed as previously described
(Eyster et al., 2007). GAPDH was used as the endogenous con-
trol (housekeeping) gene. Predesigned primers and probes
were obtained from Life Technologies (Grand Island, NY)
(Hs00607129_gH for HSPA5, Hs00355782_m1 for CDKN1A,
Hs01597588_m1 for CDKN1B, and Hs00358796_g1 for CHOP).
Data were analyzed by GraphPad Prism (GraphPad Software,
San Diego, CA).
2.6. Protein identification by mass spectrometry analysis
The proteins were obtained upon cellular fractionation to in-
crease the efficiency in the number of proteins to be detected.
The cellular pellet was resuspended in low salt buffer (10 mM
HEPES pH7.9, 10 mM KCl, 1.5 mMMgCl2) for 15 min on ice and
then homogenized using a motorized pestle. The lysate was
centrifuged at 4 C at 800 g. The supernatant constituted a
fraction enriched in cytosolic components. The pellet,
enriched mainly in membranes and organelles, was lysed us-
ing NP40 buffer (50 mM TriseHCl pH 7.5, 150 mM NaCl, 0.5%
NP40, and 50 mM NaF). The lysate was centrifuged at
10,000 g for 20 min, and the supernatant was transferred to
a new tube. The proteins obtained in both fractions in-
solution were reduced with 50mMDTT (SigmaeAldrich, Saint
Louis, MO) at 65 C for 5 min, alkylated with 100 mM iodoace-
tamide (SigmaeAldrich), and digested using sequencing grade
trypsin (Promega, Madison, WI) overnight at 37 C. The diges-
tion was stopped by the addition of 0.5% acetic acid, frozen in
dry ice, and concentrated using a Savant SpeedVac centrifuge
(Thermo Scientific, Hudson, NH). The tryptic-digested pep-
tides were dissolved in 100 mM ammonium formate pH10
and separated through 2D-nanoLC with dilution using a 2D-
nanoAcquity UPLC (Waters Corporation, Milford, MA). The
first dimension was performed in XBridge BEH130 C18, 5 mm,
300 mm  50 mm NanoEase Column (Waters Corporation, Mil-
ford, MA) using as solvent A1 20 mM ammonium formate
pH10 and B1, 100% acetonitrile (Optima LC/MS, Fisher Scienti-
fic, Pittsburgh, PA) LC-MS grade. The flow at 1st dimension
was 2 ml/min, and 11 different step gradients (dilutionmethod)
were performed for 20 min each. The second dimension
included trapping and desalting online through
180 mm  20 mm, 5 mm symmetry C18 nanoAcquity UPLC
trap column (Waters) at a flow 20 ml/min, 99% A2 (water,
0.1% formic Acid), and 1% B2 (100% acetonitrile, 0.1% formic
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 0 9 9e1 1 1 71102acid) for 20 min. After the peptides were desalted and concen-
trated, they were separated online in the second dimension
through BEH130 C18 1.7 mm, 100 mm  100 mm nanoAcquity
UPLC column. The standard solvent gradient used was:
0e2 min, 3% B2 isocratic; 2e40 min, 3e85% B2 linear, at a
flow rate of 400 nl/min for 60 min. The eluted ions were
analyzed by one full precursor MS scan (400e1500 m/z) fol-
lowed by four MS/MS scans of the most abundant ions
detected in the precursor MS scan while operating under dy-
namic exclusion or direct data acquisition system (DDAS).
Spectra obtained in the positive ion mode with nano ESI-Q-
Tof Synapt G1mass spectrometer (Waters) were deconvoluted
and analyzed using the MassLynx software 4.1 (Waters). A
peak list (PKL format) was generated to identifyþ1 or multiple
charged precursor ions from the mass spectrometry data file.
The instrument was calibrated in MS/MSmode using 100 fmol
of (Glu1)-Fibrinopeptide B human (Sigma) with a RMS residual
of 3.857 e4 amu or 6.9413 e1 ppm or 7.722 e0 ppm. Parent
mass (MS) and fragment mass (MS/MS) peak ranges were
400e1500 Da and 65e1500 Da, respectively. Mascot server
v2.5.0 and Mascot Daemon Toolbox v2.5.1 (www.matrix-sci-
ence.com, UK) in MS/MS ion search mode (local licenses)
were applied to conduct peptide matches (peptide masses
and sequence tags) and protein searches against NCBInr
v20150531 (67337701 sequences, 24122812982 residues) taxon-
omy filter (Homo sapiens) (311623 sequences) and IPI Human v
3.80 (86719 sequences, 34928216 residues). The following pa-
rameters were set for the search: carbamidomethyl (C) on
cysteine was set as fixed; variable modifications included
asparagine and glutamine deamidation and methionine
oxidation. One missed cleavage was allowed; monoisotopic
masses were counted; the precursor peptide mass tolerance
was set at 50 ppm; fragment mass tolerance was 0.3 Da, and
the ion score or expected cut-off was set at 5. The MS/MS
spectra were searched with MASCOT using a 95% confidence
interval (C.I. %) threshold (p < 0.05). A minimum score of 46
was used for peptide identification. The protein redundancy
that appeared at the database under different gi (protein
accession number) was limited to human with the first prior-
ity assigned to that specie.
2.7. Western blot analysis
Following treatment, cells were harvested, washed with PBS,
pelleted, and maintained at 80 C until whole cell extracts
were prepared. Cell lysates were obtained, protein quanti-
tated, and subjected to gel electrophoresis and western blot-
ting as previously described (Gamarra-Luques et al., 2012).
The list of antibodies and the dilutions utilized are described
in Table S1.
2.8. Xbp1 mRNA splicing
Total RNAwas isolated using TRIzol (Invitrogen, Carlsbad, CA)
per manufacturer’s instructions. Reverse transcription (RT)
reaction and polymerase chain reaction (PCR) were done using
a SuperScript first-strand synthesis system for RT-PCR (Invi-
trogen). The forward primer for PCR amplification of spliced
and total human Xbp1 mRNA was 50-CCTGGTTGCTGAAGAG-
GAGG-30 and the reverse primer was 50-CCATGGGGAGTTCTGGAG-30. For ACTB (b-actin), the primers
were 50-CCTGTACGCCAACACAGTGC-30 (forward) and 50-
ATACTCCTGCTTGCTGATCC-30 (reverse). PCR was carried out
with an initial cycle at 94 C for 3 min, followed by 35 cycles
at 94 C for 30 s, 58 C for 30 s, and 72 C for 30 s with a final
extension at 72 C for 5 min. The size of amplified unspliced
Xbp1mRNA is 145 base pairs (bp), the size of amplified spliced
Xbp1mRNA is 119 bp, and the size of amplified ACTB (b-actin)
mRNA is 211 bp. The PCR products were run on a 2% agarose
gel, stained with ethidium bromide (Molecular Probes), and
photographed under UV light. A DNA marker (Bionexus Lo
DNAmarker) was used to determine the size of the PCR prod-
ucts (Bionexus, Oakland, CA).
2.9. Puromycin incorporation assay
Puromycin is an aminoacyl-tRNAmimetic that enters the site
A of the ribosome and terminates translation prematurely.
However, when exposure to puromycin is done short before
ending an experiment, conjugation of puromycin with
nascent polypeptide chains generate short-lived puromycy-
lated peptides that are released from the ribosome and can
be detected with an anti-puromycin antibody by western
blot. Incorporation of puromycin into nascent amino acid
chains is a sensitive indicator of instant or ongoing mRNA
translation rate as one molecule of puromycin is incorporated
per nascent peptide (Liu et al., 2012; Schmidt et al., 2009). For
each experiment, puromycin (Sigma) was pulsed to the cul-
ture media to a final concentration of 1 mM at 37 C for
30 min. Thereafter, cells were harvested and processed for
western blot analysis of puromycylated peptides.
2.10. Assessment of the activity of the proteasome
We transiently transfected ovarian cancer cells with an
expression plasmid termed GFPu using Effectene transfection
reagent (Qiagen). GFPu (Li et al., 2011) is a modified, enhanced,
green fluorescence protein (EFGP) driven by a cytomegalovirus
promoter; it carries an ubiquitination signal sequence (CL1
degron, ACKNWFSSLSHFVIHL) that is used as surrogate sub-
strate for the proteasome (Bence et al., 2001). In the absence
of changes in synthesis, GFPu protein abundance, as assessed
by fluorescence microscopy or western blot, inversely reflects
proteasome proteolytic function (Dong et al., 2004). The
caspase-like (B1) peptidase activity in vitro was done as previ-
ously described (Li et al., 2011). We used the synthetic fluoro-
genic peptide Suc-LLE-AMC with or without ATP and in the
presence or absence of MG-132. The fraction of the activity
that was inhibited by MG-132 was attributed to the
proteasome.
2.11. Drug interaction analysis
To characterize the pharmacological interaction between
mifepristone and chloroquine, and mifepristone and bortezo-
mib, we used the CalcuSyn software (Biosoft, Cambridge, UK),
which utilizes the combination index (CI) as a method for
quantifying drug interaction. We previously described in
detail the calculation of the CI (Gamarra-Luques et al., 2012).
Briefly, for a specific drug association, a CI < 1 indicates
Figure 1 e OV2008 (p53 wt/platinum sensitive), OV2008/C13 (p53 wt/platinum resistant), and SKOV-3 (p53 null/platinum semi-resistant) cells
were cultured in the presence of DMSO (vehicle), 10, 20, or 30 mMmifepristone for 7 days. The values of concentrations of the drug causing 50%
inhibition of growth (GI50) were calculated using software (Calcusyn, Biosoft) designed to study drug interaction that analyzes the median
effective dose or Dm, which is analogous to the GI50. The experiments were run 3 times in triplicates for each cell line.
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CI ¼ 1 indicates additivism, whereas CI > 1 indicates
antagonism.3. Results
3.1. Mifepristone inhibits the growth of ovarian cancer
cells of different genetic backgrounds and platinum
sensitivities
We first confirmed the anti-growth capacity of mifepristone
on three ovarian cancer cell lines, one sensitive to platinum
and carrying wild-type p53 (OV2008), its sibling cell line resis-
tant to platinum yet maintaining wild-type p53 (OV2008/C13),
and the platinum semi-resistant and p53 null, SKOV-3 cell line
(Freeburg et al., 2009a). The growth inhibition curves are
shown in Figure 1. The concentration needed to inhibit 50%
of growth (GI50) ranged from 8 to 14 mM, confirming our previ-
ous assessment with these cell lines in which mifepristone at
concentrations up to 20 mM was cytostatic, whereas at higher
concentrations it had lethal effects (Freeburg et al., 2009a;
Goyeneche et al., 2012).
3.2. Functional genomic and proteomic analyses of
mifepristone-treated ovarian cancer cells
To identify genes and proteins differentially regulated by
mifepristone, we exposed the ovarian cancer cells to aTable 1eGenes differentially expressed upon exposure to 20 mMmifeprist
status as detected by DNA microarray analysis and expressed as fold chan
Symbol Gene description OV2
ZNF488 Zinc finger protein 488 2.
S100P S100 calcium binding protein P 9.
DDIT3 DNA-Damage-Inducible Transcript 3/CHOP 6.
UNC5B Unc-5 homolog B (C. elegans) 2.
TRIB3 Tribbles homolog 3 (Drosophila) 6.
CHAC1 Cation transport regulator homolog 1 (E. coli) 4.cytostatic 20 mM concentration of mifepristone for 24 h. A
DNA microarray analysis identified six genes (ZNF488, S100P,
DDIT3, UNC5B, TRIB3, and CHAC1) differentially expressed
in the three cell lines, being then unrelated to platinum sensi-
tivity or p53 status (Table 1). There were also several genes
significantly downregulated and upregulated regardless of
platinum sensitivity (Figure S1 and Tables S2 and S3). Ingenu-
ity Pathway Analysis (IPA) of genes differentially regulated by
mifepristone in two cell lines (OV2008 and OV2008/C13) iden-
tified the ER stress and the unfolded protein response (UPR)
pathways as the top candidates significantly affected by mife-
pristone (Tables S4 and S5).
We also found differentially expressed proteins in
response to 20 mM mifepristone for 24 h using a 2D nanoLC-
MS/MS proteomic approach (Figure 2 and Tables S6 and S7).
For this initial screening we found notably increased, in all
ovarian cancer cells exposed to cytostatic doses of mifepris-
tone, a mRNA encoding for DNA-damage inducible transcript
3 (DDIT3), also known as CCAAT-enhancer-binding protein
homolog protein (CHOP) or GADD153 (Growth arrest and
DNA damage inducible gene 153) (Oyadomari and Mori, 2004)
(Table 1). Using the proteomic platform, it was clear that the
main protein consistently and significantly upregulated by
mifepristone in the three cell lines was GRP78 (glucose-regu-
lated protein, 78 kDa), a member of the family of heat shock
proteins of 70 kDa, also termed BIP (binding immunoglobulin
protein) or heat shock 70 kDa protein 5 (HSPA5) (Figure 2).
GRP78 is the master chaperone of the ER (Lee, 2014). Together,
CHOP and GRP78were proposed to balance the stress of the ERone for 24 h regardless of the sensitivity of the cells to cisplatin and p53
ges when compared to vehicle-treated controls.
008 OV2008/C13 SKOV-3 Protein class
99 2.92 1.95 Transcription factor
49 3.41 2.02 Signaling molecule
06 5.41 2.08 Transcription factor
81 2.94 3.90 Receptor
47 4.63 2.21 Protein kinase
34 4.78 2.01 Cation transporter
Figure 2 e Venn diagram displaying differentially expressed proteins in response to 24 h exposure to 20 mM mifepristone as detected by 2D-
nanoLC-mass spectrometry (MS/MS). The experiment was conducted 3 times in triplicate for each cell line.
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survival factor) manner (Schonthal, 2013). We further
confirmed the expression of these differentially regulated pro-
teins by western blot. Figure 3A shows that GRP78 and CHOP
were upregulated by 20 mM mifepristone in a time-
dependent manner in all cell lines studied. As control for
mifepristone-mediated cytostatic activity, we measured the
increased expression of the cyclin-dependent kinase inhibi-
tors p27kip1 and p21cip1, both previously shown to mediate
cell cycle arrest induced by mifepristone (Goyeneche et al.,
2007, 2012). Additionally, we validated the DNA microarray
data for four genes in OV2008 cells: p21cip1, p27kip1, GRP78,
and CHOP. We confirmed that p21cip1, GRP78, and CHOP
mRNA levels increased in response to mifepristone by using
a real-time RT-PCR approach, whereas p27kip1, which
increased in response to mifepristone at the level of protein
abundance, did not significantly change at the level of
mRNA (Figure 3B). This latter finding was in agreement with
the fact that p27kip1 is known to be regulated post-
transcriptionally (Slingerland and Pagano, 2000).
3.3. Mifepristone triggers the unfolded protein response
Because mifepristone upregulated two key proteins involved
in the ER stress response (CHOP and GRP78), we studied the
expression of other proteins involved in ER stress-related ho-
meostasis, as well as compared the effect of mifepristone
against those of two well-known ER stressors, thapsigargin
and tunicamycin. Thapsigargin causes ER stress by blocking
calcium channels in the ER membrane (Chen et al., 2000),
whereas tunicamycin is a glycosidase inhibitor, causingaccumulation of non-glycosylated proteins that are incapable
of being exported from the ER (Miyake et al., 2000; Noda et al.,
1999). Figure 4A shows that thapsigargin and tunicamycin
caused remarkable increase in the abundance of GRP78, which
was more marked than that caused by mifepristone. In addi-
tion, the three drugs were similarly potent in increasing the
expression of the ER chaperone protein disulfide isomerase
(PDI) and the sensor of the unfolded protein response (UPR),
inositol-requiring protein 1 (IRE1). None of the compounds,
however, significantly changed the levels of other ER chaper-
ones such as endoplasmic oxidoreductin-1-like protein
(ERO1a) and calcium-binding protein, calnexin (Gutierrez
and Simmen, 2014).We further observed that the downstream
transcription factor involved in the UPR, ATF4, was increased
by the three drugs, but more potently by thapsigargin when
compared to tunicamycin or mifepristone.
To demonstrate that the effect of mifepristone was not
steroid-structure related, we compared the expression of the
ER stress-related proteins GRP78 and IRE1 and that of the
cell cycle inhibitor p21cip1 in response to mifepristone, against
their responses to the related synthetic steroid and glucocor-
ticoid agonist, dexamethasone. Figure 4B shows that cell cycle
arrest, anticipated by the increase in p21cip1, and ER stress
response, marked by the upregulation of GRP78 and IRE1,
were induced by mifepristone but not by an equimolar con-
centration of dexamethasone, indicating the specificity of
the mifepristone-induced ER stress response.
To maintain homeostasis when the load of unfolded pro-
teins exceeds the folding capacity of the ER, GRP78 detaches
from the ERmembrane sensors PERK, IRE1, and ATF6, and un-
leashes the UPR (Clarke et al., 2014; Gardner et al., 2013;
Figure 3 e OV2008, OV2008/C13, and SKOV-3 cells were exposed to 20 mM mifepristone for 12, 24, 36, 48, or 72 h (Hs). At the end of the
experiments, cells were subjected to RNA and protein isolation. (A) Western blot analysis of cell cycle inhibitors p21cip1 and p27kip1, and of ER
stress proteins GRP78 and CHOP. Results shown are representative of 3 separate experiments. (B) Comparison of the expression of the mRNA
encoding for the indicated proteins as detected by DNA microarray and real-time RT-PCR in OV2008 cells. This experiment was done 3 times in
triplicate. Statistical analysis was done using Student’s t-test.
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eeresponse experiment to determine the induction of various
components of the UPR pathway by mifepristone. We
assessed the activation of the pathway downstream of PERK
by measuring the increases in transcription factors ATF4
and CHOP, which occurred following a same trend in
mifepristone-treated cells when compared to tunicamycin-
treated cells (Figure 4C, upper panels). The UPR sensor IRE1
was upregulated and phosphorylated upon 48 h of cellular
exposure to tunicamycin or mifepristone (Figure 4C, middle
panels). Finally, a third branch of the UPR pathway driven by
the activation of ATF6 was activated by tunicamycin and
mifepristone as demonstrated by the increase in the cleaved
product of ATF6 formed upon trafficking of ATF6 from the
ER to the Golgi apparatus, where it is cleaved to release the sol-
uble transcription factor (sATF6) (Figure 4C, lower panels). The
induction of the ER stress response by mifepristone was dose-
dependent (Figure 4C); for instance, cells treated with 20 mM
mifepristone show increases in the expression of UPR related
proteins that were smaller in magnitude (e.g. GRP78, CHOP,
and IRE1a), or occurred later in time (e.g. ATF4, CHOP, andsATF6), when compared to cells treated with 40 mM
mifepristone.
3.4. Mifepristone increases mRNA translation rate
involving the eIF2a/ATF4 pathway
One homeostatic mechanism whereby the UPR controls ER
stress as a consequence of accumulation of misfolded pro-
teins is the transient decline in the rate of mRNA translation
(Hetz, 2012; Nagelkerke et al., 2014). However, when we stud-
ied mRNA translation rate by labeling peptides with puromy-
cin, we found that mifepristone caused a time-related
increase in protein synthesis lasting approximately 36 h
(Figure 5A). Such increase in global protein puromycylation
was dose-dependent up to 5 mM mifepristone, reaching a
plateau at doses of 10 and 20 mM. The accumulation of
GRP78, however, kept increasingwith the dose ofmifepristone
(Figure 5B).
Polypeptide chain translation initiator factor eIF2a is a
limiting factor for protein synthesis under conditions of
cellular stress based on the capacity of its alpha subunit to
Figure 4 e (A) OV2008 cells were exposed to 20 mMmifepristone (MF) for 48 h, or to 300 nM thapsigargin (TG) or 2 mg/ml tunicamycin (TN) for
24 h. (B) The induction of GRP78 by 20 mM MF for 24 h or 48 h followed that of ER stressors TG (300 nM) or TN (2 mg/ml) used for 24 h; the
effect of MF was not mimicked by an equimolar concentration of a related steroid, dexamethasone (DEX). (C) Time-course induction of UPR-
related proteins by 20 mM MF (MF20) or 40 mM MF (MF40) in comparison to the induction achieved by the known ER stressor TN (2 mg/ml).
Results are representative of at least 2 independent experiments with a similar outcome.
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2015), thus limiting the availability of eIF2a needed for initia-
tion of translation (Bhat et al., 2015). We show that ovarian
cancer cells have elevated phosphorylation of eIF2a on Ser-
51 (p-eIF2a), which was rapidly yet temporarily diminished
by mifepristone, without affecting total levels of eIF2a, and
concurrently with an increase in puromycin incorporation
(Figure 5C and D). Mifepristone also increased the expression
of ATF4 (Figure 5D and E), which is known to be induced
more efficiently under conditions of ER stress (Koromilas,
2015; Nagelkerke et al., 2014). Increased puromycylation,
dephosphorylation of eIF2a on Ser-51, and induction of ATF4
by mifepristone, were all prevented by the protein elongation
inhibitor cycloheximide (Schneider-Poetsch et al., 2010)
(Figure 5D). To study whether mifepristone augments puro-
mycylation by increasing eIF2a availability for translation
initiation, we co-incubated ovarian cancer cells withmifepris-
tone and salubrinal, a small molecule inhibitor of the serine/
threonine protein phosphatase that removes Ser-51 phos-
phorylation from eIF2a (Boyce et al., 2005). Figure 5E shows
that salubrinal prevented mifepristone-induced Ser-51
dephosphorylation of eIF2a while diminishing mifepristone-induced puromycylation and ATF4 induction. Altogether, re-
sults shown in Figure 5 (panels AeE) suggest thatmifepristone
increases mRNA translation rate by targeting the eIF2a/ATF4
signaling pathway.
3.5. The increase in protein synthesis induced by
mifepristone contributes to the unfolded protein response
Because protein synthesis was induced by mifepristone in as-
sociation with induction of the UPR, we examined whether
such increase in mRNA translation rate was related to the
causation of ER stress and the unleashing of the UPR. We
exposed ovarian cancer cells to mifepristone and measured
the splicing of XBP1 mRNA as a non-translatable readout of
the UPR; this splicing occurs as a consequence of the RNAse
activity of activated IRE1a, and leads to the formation of a
potent transcriptional activator (XPB1s) that induces the
expression of ER chaperones and ERAD proteins (Ron and
Walter, 2007). Figure 5F shows that mifepristone triggered a
time-course dependent splicing of XPB1 mRNA similar to
that caused by the well-known ER stressor tunicamycin.
Such splicing was, however, abrogated when the cells were
Figure 5 e Mifepristone (MF) increases the incorporation of puromycin (Puro) in newly synthesized peptides. (A) Time-course upon treatment
with 20 mMMF. (B) Dose-response after treatment with MF for 24 h. (C) Effect of MF on the phosphorylation of eIF2a on Serine 51 (p-eIF2a).
(D) Effect of cycloheximide (CHX) on MF-induced puromycylation and ATF4 induction; CHX (10 mg/ml) was added to the culture concurrently
with 20 mM MF for the indicated times. (E) Salubrinal 50 mM (SAL50) or 100 mM (SAL100) and MF (20 mM) were added either individually or
concurrently for 3 h. Cultures in A,B, D and E were pulsed with 1 mM puromycin for 30 min at 37 C before stopping the experiments, and
puromycylated proteins were detected with the mouse antibody clone 12D10. IB; immunoblot. (F) Effect of 20 mM MF on the splicing of XPB1
mRNA assessed by RT-PCR; TN, tunicamycin (2 mg/ml). Arrows indicate total and spliced XPB1 mRNA variants. (G) Splicing of XPB1 mRNA
in ovarian cancer cells co-incubated for 3 h with MF and CHX (10 mg/ml); MF20, 20 mM; MF40, 40 mM. All results presented were performed in
OV2008 cells and are representative of 2 or 3 independent experiments that had a similar outcome.
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that protein synthesis is required for MF-induced UPR.3.6. Mifepristone increases autophagic flux in ovarian
cancer cells
It has been shown that induction of autophagy is a mecha-
nism of homeostasis that facilitates the elimination of long-
lived proteins (Wang and Terpstra, 2013). Autophagy is partic-
ularly active in response to ER stress and involves the catabo-
lism of proteins within double-membrane vesicles, the
autophagosomes, which fuse with lysosomes forming the
autolysosomes. In the short term, this mechanism allows for
cell survival, whereas in the long term, it leads to cell death
(Platini et al., 2010). We studied the dynamics of the process
of autophagy by assessing LC3II levels and autophagic flux.
LC3 proteins are cleaved by Atg4 generating LC3-I, which con-
jugates with phosphatidylethanolamine giving rise to a lipi-
dated product termed LC3-II. As LC3-II is degraded in
autolysosomes, its level is widely used as a marker of auto-
phagy (Barth et al., 2010). However, increase in LC3-II levels
detected by western blot may indicate either increased auto-
phagy induction or impaired autophagosome removal. Hence,
to assess if mifepristone-associated ER stress involved an in-
crease in autophagic flux, we studied LC3-II turnover in thepresence or absence of the lysosome degradation inhibitor
bafilomycin A1. If autophagy processing is increased by mife-
pristone, then LC3-II levels should increase further in the
presence of the lysosome degradation inhibitor, as the transit
of LC-3II through the autophagy pathway will be inhibited
(Zhang et al., 2013). Mifepristone was capable of increasing
the levels of LC3-II in a dose-dependent manner. Yet, such in-
crease was enhanced remarkably by bafilomycin A1
(Figure 6A). Furthermore, when mifepristone was combined
with the selective eIF2a dephosphorylation inhibitor salubri-
nal (Boyce et al., 2005), the autophagic flux was substantially
abrogated (Figure 6A). GRP78 accumulated in response to
mifepristone, but not in response to bafilomycin A1
(Figure 6A). Salubrinal ameliorated the increase in GRP78
induced by mifepristone. Moreover, salubrinal prevented the
loss of viability induced by a lethal concentration of mifepris-
tone (Figure 6B).3.7. Chloroquine increases mifepristone-induced
cytotoxicity
Chloroquine inhibits lysosomes by increasing the pH of the
lysosomal compartment, thus preventing the activity of lyso-
somal acid proteases and causing autophagosomes to accu-
mulate; it is widely used in the clinic to treat malaria and
Figure 6 e OV2008 cells were incubated for 48 h in the presence of salubrinal (SAL, 100 mM), chloroquine (CQ, 40 mM), mifepristone (MF,
40 mM), or their combinations. Viability (B) was assayed using microcytometry as previously described in detail (Freeburg et al., 2009b), whereas
protein expression (A, C) was studied by western blot using the indicated antibodies. BAF[ bafilomycin A1 (100 nM, added 1 h before ending the
experiment). *p< 0.05 vs. VEH; **p< 0.01 vs. MF (one-way ANOVA followed by NewmaneKeuls Multiple Comparison Test). Results are
representative of at least 2 independent experiments with a similar outcome.
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exposed ovarian cancer cells to lethal doses of mifepristone,
usage of chloroquine increased further the number of dying
cells (Figure 6B) in association with total cleavage of the
marker of cell death, cleaved PARP (Galluzzi et al., 2012)
(Figure 6C). The interaction amongst mifepristone and chloro-
quine was synergistic for the combinations of 10, 20 or 40 mM
mifepristone with 40 mM chloroquine (CI ¼ 0.613, 0.565, and
0.424, respectively). The lethality caused by the combination
of mifepristone with chloroquinedand assessed by
measuring viability and cleavage of PARPdwas reversed by
the presence of salubrinal, which also reduced MF-induced
GRP78 levels (Figure 6B and C).
3.8. Mifepristone potentiates the toxicity of proteasome
inhibitors
One canonical mechanism whereby the stress of the ER is
relieved is by enhancing ER-associated degradation (ERAD)
via the ubiquitin proteasome system (UPS), in which mis-
folded proteins are recognized and retro-translocated to the
cytoplasm where they are ubiquitinated and targeted for pro-
teasome degradation (Brodsky, 2012; Vembar and Brodsky,
2008). We first studied whether the ER stress induced by mife-
pristone associatedwith a compensatory increase in the activ-
ity of the UPS. We assessed the accumulation of poly-
ubiquitinated proteins as a surrogate marker of proteasome
activity (Bedford et al., 2011; Wang and Terpstra, 2013). Thelevel of poly-ubiquitinated proteins did not change much
when comparing cells treated with mifepristone against cells
treated with tunicamycin, whereas the overall ubiquitination
of drug-treated cells was not different from that depicted in
vehicle-treated cells, suggesting that neither tunicamycin
nor mifepristone affect the activity of the proteasome
(Figure 7A).
We next rationalized that by causing ER stress, mifepris-
tone may interact with proteasome inhibitors blocking
ovarian cancer cell growth; this is because lack of ERAD/26S
proteasome function would eliminate one critical relief
mechanism for an ER overwhelmed by mifepristone-
induced accumulation of misfolded/unfolded proteins. We
exposed cells to various concentrations of the proteasome in-
hibitor MG-132 and found that doses up to 0.25 mM did not kill
the cells and did not accumulate poly-ubiquitinated proteins
whereas doses of 0.50 mM and higher were sufficient to block
the proteasome and to kill the cells as demonstrated by the
accumulation of poly-ubiquitinated proteins (Figure 7B) and
cleavage of PARP (Figure 7C). We then exposed ovarian cancer
cells to various concentrations of mifepristone in the pres-
ence or absence of a non-killing concentration of MG-132. Re-
sults in Figure 7D show that, while in a range of 2.5e20 mM
mifepristone did not kill the cells, when combined with a
non-lethal dose of MG-132 (0.25 mM), it triggered cell death
in a dose-dependent manner. At the 0.25 mM dose used,
MG-132 alone did not accumulate poly-ubiquitinated pro-
teins, but it did so when it was combined with 20 mM
Figure 7 e (A) Neither mifepristone (MF) (MF20, 20 mM; MF40, 40 mM) nor tunicamycin (TN; 2 mg/ml) impact the processing of poly-
ubiquitinated proteins ([Ub]n) in OV2008 cells. Concentrations of MG-132dan inhibitor of the proteasomed0.5 mM or higher cause
accumulation of [Ub]n (B) and lethality (C). (D) Reduced viability of OV2008 ovarian cancer cells exposed for 72 h to a range of cytostatic
concentrations of MF and a fixed (0.25 mM) cytostatic dose of MG-132 as determined using microcapillary cytometry. Lethal interaction between
MG-132 and MF for 72 h involves accumulation of [Ub]n (E), accumulation of p21cip1, and cleavage of PARP (FL [ full length; C [ cleaved)
(F). GAPDH or b-actin were used as loading controls. Results are representative of at least 2 independent experiments with a similar outcome.
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stress induced by mifepristone allowed a sub-optimal dose
of MG-132 to cause proteasome functional insufficiency.
The toxicity of this drug combination was further evidenced
by the cleavage of PARP and p21cip1 (Galluzzi et al., 2012)
(Figure 7F).
MG-132 is useful for laboratory investigation but has not
reached the clinic; hence, we tested the previous concept us-
ing bortezomib, approved for the treatment of multiple
myeloma and mantle cell lymphoma (Buac et al., 2013). We
found that 5 nM bortezomib was sufficient to kill w60%
ovarian cancer cells when combined with a cytostatic dose
of mifepristone (Figure 8A). The interaction among mifepris-
tone and bortezomib was synergistic for the combinations of
5 and 10 nM bortezomib with 20 mM mifepristone (CI ¼ 0.389
and 0.685, respectively).
Five nM bortezomib or 20 mM mifepristone alone did not
accumulate poly-ubiquitinated proteins. Such accumulation,
however, occurred when the drugs were combined
(Figure 8B). The inhibition of the activity of the proteasome
by the combination of 5 nM bortezomib with 20 mM mifepris-
tone was further confirmed by the accumulation of the surro-
gate substrate GFPu (Figure 8C and D) and the inhibition of the
caspase-like peptidase activity of the proteasome (Figure 8E).
Such effects observed with the drug combination (i.e. 5 nM
bortezomib/20 mM mifepristone) were similar to those
observed when bortezomib was used alone but at an effective
proteasome inhibitory concentration of 20 nM, as demon-
strated by the accumulation of poly-ubiquitinated proteins(Figure 8B) and of GFPu (Figure 8C and D), and by the decline
in the caspase-like activity of the 20S proteasome
(Figure 8E). Also at the 20 nM concentration, bortezomib
monotherapy induced ER stress judged by the accumulation
of GRP78 (Figure 8F) and triggered cell death (Figure 8G).
Mifepristone alone, as previously described, caused accu-
mulation of GRP78 and IRE1, whereas bortezomib, at the
sub-optimal dose of 5 nM did not (Figure 8F). Cells exposed
to the combination of 5 nM bortezomib with 20 mM mifepris-
tone depicted as much GRP78 and IRE1 as cells receivingmife-
pristone alone (Figure 8F). The combination of 5 nM
bortezomib with 20 mM mifepristone induced accumulation
of p21cip1 beyond that caused by mifepristone alone, while
inducing cleavage of caspase-3 and of downstream substrate
PARP (Figure 8G). These results indicate that when mifepris-
tone and bortezomib are combined, the cells undergo
caspase-associated cell death.
Salubrinaldthe selective eIF2a dephosphorylation inhibi-
tor and cytoprotector against ER stressors (Boyce et al., 2005;
Gao et al., 2013; Gong et al., 2012)drescued the cells from
the toxicity of high-dose mifepristone as shown by cell sur-
vival (Figure 9A) and cleavages of caspase-3 and PARP
(Figure 9C), and prevented mifepristone-induced accumula-
tion of GRP78, CHOP and LC3II (Figure 9C and D). However,
in cells subjected to the toxicity of the combination mifepris-
tone/bortezomib, salubrinal only in part ameliorated lethality
(Figure 9A), slightly reduced the levels of GRP78 (Figure 9C) and
CHOP (Figure 9D), but did not prevent the accumulation of
poly-ubiquitinated proteins (Figure 9B).
Figure 8 e OV2008 cells were exposed for 48 h to 20 mM mifepristone (MF), 5 nM bortezomib (BZ5), 20 nM BZ (BZ20), or the combination of
20 mM MF with 5 nM BZ, and viability was assessed (A). Proteins were isolated, electrophoresed, and subjected to western blot for poly-
ubiquitination (B), ER stress-related proteins (F), and cyclin dependent kinase inhibitors p21cip1 and p27kip1, caspase-3, and PARP (G). In a
separate experiment, the peptidergic activity of the proteasome was measured in response to similar treatments (E). To further assess the activation
of the proteasome in response to cytostatic doses of BZ (5 nM) and MF (20 mM), the cells were transfected with a plasmid expressing GFPu, a
green fluorescence protein with carboxyl fusion of an ubiquitination signal sequence (degron CL1); accumulation of GFPu correlates with a
reduction in the activity of the proteasome. Panel (C) shows the accumulation of GFPu via fluorescence microscopy (scale bar[ 50 mm), whereas
panel (D) shows GFPu accumulation by western blot analysis. Results are representative of at least 2 independent experiments with a similar
outcome.
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Cancer cells, when compared to non-cancer cells, operate
with increased expression of ER stress-related proteins and a
prevalent UPR, a phenomenon coined as ER aggravation
(Schonthal, 2013) or UPR addiction (Nagelkerke et al., 2014);
this allows the cancer cells to heavily rely on the UPR for sur-
vival in the environment within which they usually prolifer-
ate: reduced nutrients, acidosis, energy deficiency, and low
oxygen tension (hypoxia) (Giampietri et al., 2015; Healy et al.,
2009; Nagelkerke et al., 2014; Schonthal, 2013). Two ap-
proaches are under exploration to target the ER in cancer cells:
(i) inhibition of the compensatory UPR components usually
hyperactive in malignant cells (e.g. developing GRP78 inhibi-
tors); and (ii) further increasing ER stress using ER stress
aggravators. In this work we provide evidence that mifepris-
tone is a potent stressor of the ER in ovarian cancer
cellsdhence, an ER stress aggravatordthus supporting the
second therapeutic approach.
For the first time in ovarian cancer cells, we show that
mifepristone induces ER stress as suggested by the activationof all arms of the UPR. We demonstrate that mifepristone,
despite not affecting the activity of the proteasome directly,
potentiates the effect of proteasome inhibitors in killing
ovarian cancer cells. We showed this in ovarian cancer cells
with functional p53 (Figures 7 and 8), and in p53 deficient
ovarian cancer cells (Figure S2). Likewise, other compounds
have been shown to potentiate the action of proteasome in-
hibitors when increasing ER stress. For instance, the toxicity
of bortezomib was enhanced by ER stressors and dysregula-
tors of the UPR such as TNF in colon cancer cells (Nowis
et al., 2007), the multi-kinase inhibitor sorafenib in hepatic
cancer cells (Honma and Harada, 2013), eayarestatindan in-
hibitor of the ER associated ATPase p97 that retro-
translocates proteins from the ER to the proteasomedin cervi-
cal cancer cells (Brem et al., 2013), Bcl-2 antagonists in diffuse
lymphocytic B-cell lymphoma (Dasmahapatra et al., 2009),
tunicamycin and thapsigargin in pancreatic cancer cells
(Nawrocki et al., 2005), and photodynamic therapy in cervical
cancer cells (Szokalska et al., 2009). In ovarian cancer cells,
bortezomib increased the toxicity of TRAIL (Saulle et al.,
2007), histone deacetylase inhibitors (Bazzaro et al., 2008;
Fang et al., 2011), carboplatin (Al-Eisawi et al., 2013), and the
Figure 9 eOV2008 cells were incubated with mifepristone (MF; 40 mM), salubrinal (100 mM), bortezomib (5 nM), or a combination of the two for
48 h. (A) Viability was detected by cytometry of cells treated with the depicted drugs. *p< 0.05 vs. vehicle; **p< 0.01 vs. MFD BZ; ***p< 0.001
vs. vehicle (one-way ANOVA followed by Tukey’s Multiple Comparison Test). (B) Poly-ubiquitination ([Ub]n) of proteins as detected by western
blot. (C) Expression of caspase-3 and its cleavage forms, the caspase-3 downstream substrate PARP, and ER master chaperone GRP78. (D)
Accumulation of LC3-II caused by MF and its prevention by the small molecule salubrinal (SAL). Also shown is the transcription factor CHOP
upregulated by MF. Results are representative of at least 2 independent experiments with a similar outcome.
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2012). Here we show that mifepristone-induced ER stress
aggravation, combined with proteasome inhibition, provides
preclinical therapeutic advantage towards ovarian cancer
cellsdi.e. lethalitydwhen compared to either compound
used individually.
We also report for the first time thatmifepristone increases
autophagic flux in ovarian cancer cells. Increase in autophagy
has been shown to be a homeostatic mechanism that bal-
ances the accumulation of unfolded or misfolded proteins in
the ER (Nagelkerke et al., 2014). For instance, ER stress and
autophagy were observed in human endothelial cells in
response of oxidized low-density lipoproteins (Muller et al.,
2011) and in mouse embryo fibroblasts and human lung can-
cer cells in response to the protease inhibitor nelfinavir
(Johnson et al., 2015). The increase in autophagic flux by mife-
pristone may be a compensatory mechanism to diminish ER
workload; this is because mifepristone-induced LC-3II accu-
mulation was completely abrogated by salubrinal, which is
an inhibitor of eIF2a dephosphorylation that protects cells
from the toxicity caused by several ER stressors (Boyce et al.,
2005; Gong et al., 2012; Matsuoka and Komoike, 2015). Further-
more, we show that induction of autophagy aftermifepristone
may have a survival purpose as the cells diewhen induction ofautophagy is prevented by adding the lysosome inhibitor chlo-
roquine. Such toxicity, however, seems to involve the eIF2a/
ATF4 branch of the UPR, as it was reversed by salubrinal.
Thus, we can conclude that ovarian cancer cells respond to
mifepristonewith ER stress, and, downstream of it, autophagy
as a manner to limiting the toxicity of the synthetic steroid.
Another novel finding in this work was the acute increase
in mRNA translation rate induced by mifepristone. Usually,
cells that are under ER stress temporarily down-regulate
global translation, while unleashing the translation of a sub-
set of mRNAs with upstream open reading frames (uORFs) in
their 50 untranslated region (50UTR) and resistant to eIF2a
repression (Andreev et al., 2015); such are the cases of tran-
scripts encoding for ATF4, CHOP, and TRIB3 (Barbosa et al.,
2013), or transcripts with intra-ribosomal entry sites (IRES) in
their 50UTR that are translated via a cap-independent mecha-
nism, such as the transcript encoding for the Cdk inhibitor
p27kip1 (Gopfert et al., 2003). This phenomenon has the pur-
pose of alleviating the ER from accumulated misfolded and/
or unfolded proteins, thus preventing ER-mediated cell death
due to proteotoxicity (Hetz, 2012). In our studies, however, the
acute increase in protein synthesis by mifepristone in ovarian
cancer cells was accountable for the UPR triggered by the ste-
roid, since mifepristone-induced XPB1 mRNA cleavage was
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in protein synthesis rate upon mifepristone exposure may
cause ER protein overload leading to ER stress, which it is
then ameliorated by a compensatory UPR.
The increase in mRNA translation rate by mifepristone in-
volves the temporary reduction of eIF2a phosphorylation on
Ser-51 (p-eIF2a). This result is relevant as the pharmacological
inhibition of this particular phosphorylation site was pro-
posed to be key to impair tumor growth using combination
anti-cancer agents, particularly in cancer cells having
increased basal eIF2a Ser-51 phosphorylation (Koromilas,
2015; Koromilas and Mounir, 2013), as it is the case for the
ovarian cancer cells studied in the present work. Supporting
this concept, the small molecule GSK2656157, which is an
ATP-competitive inhibitor of the activity of PERK (Axten
et al., 2012)dthe kinase that phosphorylates eIF2a on Ser-51
under conditions of ER stressdsignificantly reduced the
growth of tumors induced by human pancreatic and multiple
myeloma cancer cells in immunosuppressed mice (Atkins
et al., 2013).
Investigations support the idea that increased protein syn-
thesis in response to ER stress may induce cell death as a
consequence of the simultaneous transcriptional induction
of ATF4 and CHOP, ATP depletion, increase in oxidative stress,
and expression of genes that promote further load of proteins
within the ER (Han et al., 2013; Marciniak et al., 2004). Here we
show that ATF4 is induced in response to mifepristone, and it
is followed by the up-regulation of CHOP, a target of ATF4.
Another evidence for a positive contribution of increased pro-
tein synthesis to mifepristone-induced toxicity is the fact that
cycloheximide significantly mitigated the lethality induced by
the combination mifepristone/bortezomib (Figure S3). Our re-
sults provide further support to the chemotherapeutic utility
of emerging compounds that de-repress protein translation
in the face of increased levels of ER stress (Sidrauski et al.,
2013), which is a condition under which most cancer cells
operate.
The activation of the ER stress response by mifepristone is
further evidenced by the significant upregulation of CHAC1 in
all cell lines studied. This gene was defined as a cation trans-
port regulator-like protein 1, acting in ER-stress mediated cell
death downstream of ATF-4 and CHOP (Mungrue et al., 2009).
Supporting an active role of ATF4 and CHOP in the killing of
ovarian cancer cells when mifepristone was used at lethal
doses, or when it was used at cytostatic doses but combined
with either a proteasome inhibitor or an autophagy inhibitor,
is the remarkable capacity of mifepristone to induce expres-
sion of TRIB3, which was described as an ER stress gene
induced by ATF4-CHOP, and demonstrated to be involved in
cell death (Ohoka et al., 2005). Another piece of evidence sup-
porting the effect of mifepristone-induced eIF2a-ATF4-CHOP
pathway in the phenotype of the cells, is the induction of auto-
phagy as ATF4-CHOP are required for the transcription of
several genes involved in the formation and functioning of
the autophagosome upon amino acid starvation, ER stress,
or hypoxia (B’Chir et al., 2013; Rzymski et al., 2010).
In addition to the genes related to the ER stress response,
we also discovered genes differentially expressed by mife-
pristone and encoding for structural proteins as well as pro-
teins involved in various functions within the cells,including metabolic and cell communication processes. Us-
ing the known proteins affected by mifepristone and
involved in cell cycle arrest which we previously discovered
(Cdk2 and its regulators), and adding the genes differentially
expressed by mifepristone in the three ovarian cancer cell
lines regardless of sensitivity to platinum and p53 back-
ground (see Table 1), we performed a pathway building anal-
ysis that led to the development of several predicted
regulatory pathways that should be the subject of further
hypothesis-driven studies (Figure S4 and Table S8). Based
on published literature, the pathway building analysis pre-
dicted the interconnection among all genes utilized for the
analysis. For instance, the analysis projected that upregula-
tion of the calcium binding protein S100P leads to downregu-
lation of Bcl-2 (Shimamoto et al., 2014), which we found to be
true when mifepristone induced cell death in combination
with PI3K inhibitors (Wempe et al., 2013). S100P is predicted
to increase expression of ezrin, which is confirmed in our re-
sults in SKOV-3 cells (see Table S6). Ezrin links the plasma
membrane and the actin cytoskeleton (Algrain et al., 1993),
which we previously demonstrated becomes dysregulated
by mifepristone (Brandhagen et al., 2013). It is likely that
ezrin also plays a role in mediating mifepristone-induced
dysregulation of cellular adhesion, migration, and actin cyto-
skeleton organization. This is because ezrin inhibits E-cad-
herin (CDH1) (Hunter, 2004; Li et al., 2008) and, in this
manner, can mediate the morphological alterations caused
by mifepristone we previously described (Brandhagen et al.,
2013). The pathway analysis also anticipated that upregula-
tion of HSPA5 (GRP78) should negatively affect caveolin-1
(CAV1) (Moon et al., 2015); indeed, CAV1 was shown to be
downregulated by mifepristone (see Table S6). Caveolin-1
may link mifepristone activity with the augmented autopha-
gic flux as predicted in the pathway analysis by the regula-
tion of proteins involved in autophagy (Figure S3). This is
relevant considering that caveolin-1 facilitates the interac-
tion between Fas and LC3B (Tanaka et al., 2012), two proteins
predicted to be affected by mifepristone. Two more predic-
tions were the regulations between CHOP (DDIT3) and the
pseudokinase TRIB3 (Ohoka et al., 2007), and the upregula-
tion of CHAC1 by CHOP (Mungrue et al., 2009) we show in
this study. Finally, another evidence relevant to our studies
is that ZNF488, shown to enhance migration and invasion
of nasopharyngeal cancer cells (Zong et al., 2016), was signif-
icantly downregulated by mifepristone in all cell lines stud-
ied (see Table 1). Thus, it is possible that ZNF488 mediates
the inhibition of migration and invasion induced by mife-
pristone in ovarian cancer cells (our unpublished observa-
tions). The predictive pathways set in motion by
mifepristone and developed when combined hypothesis-
driven and discovery-based approaches (depicted in
Figure S4) will need validation in future investigations to un-
leash their roles in mifepristone-mediated effects towards
ovarian cancer cells, such as cell growth inhibition, activa-
tion of the UPR, modification in morphology, cytoskeleton
dynamics, adhesion and migration of the cells, and activa-
tion of autophagy.
Mifepristone has been shown to be an antiprogestin and an
antiglucocorticoid agent; thus, it can be assumed that it drives
its anti-ovarian cancer effect impacting either progesterone
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 0 9 9e1 1 1 7 1113receptors (PR) or glucocorticoid receptors (GR). With respect to
PR, evidence shows that presence of ‘classical’ (nuclear) PR is
not required for mifepristone to block the growth of various
types of cancer cells, including ovarian cancer cells (Tieszen
et al., 2011). The same concentrations of mifepristone we
used to induce growth arrest in our previous work were
used in the current study to induce ER stress in ovarian cancer
cells expressing or not expressing PR. Thus, we rationalize
that the presence of ‘classical’ PR is not required for the induc-
tion of the ER stress response and would not impact the usage
of this drug for anti-ovarian cancer therapy.
It is possible, however, that GR may drive the anti-growth
effect and ER stress induction by mifepristone. There are
two isoforms of GR, GRa and GRb. Evidence supports GRa as
driving GR-mediated transactivation activity, whereas GRb
functions as a dominant negative inhibitor of GRa
(Taniguchi et al., 2010). Our laboratory has shown that mife-
pristone blocked growth of cancer cells that have negligible
expression of GRa, including OVCAR-3 ovarian cancer cells
(Tieszen et al., 2011), suggesting that the presence of GRa
may not be required for the anti-proliferative action of mife-
pristone. It remains to be assessed if GRb, which is ubiqui-
tously present in all cancer cell lines we so far studied
(Tieszen et al., 2011), and is able to bind mifepristone and
transactivate genes in the absence of GRa (Kadmiel and
Cidlowski, 2013; Lewis-Tuffin et al., 2007), plays a role in the
anti-growth effect and ER stress response induced by the syn-
thetic steroid.
The three drugs utilized in this work, mifepristone, chloro-
quine, and bortezomib, are already used in the clinic.Figure 10 e Schematic model whereby ER stress aggravation triggered by m
or lysosomal inhibition (A) leading to cell death. AF: autophagic flux; ERA
ubiquitin proteasome system; CQ: chloroquine; BZ: bortezomib.Mifepristone is utilized to terminate early pregnancies (work-
ing as an antiprogestin) (Newhall and Winikoff, 2000) and to
ameliorate hyperglycemia in patients with endogenous Cush-
ing’s syndrome (working as an antiglucocorticoid) (Fleseriu
et al., 2012). Chloroquine is used to treat malaria (Solomon
and Lee, 2009), and bortezomib is prescribed for the treatment
of multiple myeloma and mantle cell lymphoma (Buac et al.,
2013). Hence, the systemic toxicity and tolerability studies for
these compounds have already been performed, making
them valuable candidates for rapid repurposing for cancer
therapy.
In summary, in this work we combined unbiased genomic
and proteomic tools with hypothesis-driven approaches to
discover and validate the effect of mifepristone as a potent
stressor of the ER leading to the induction of the UPR. We pro-
vide evidence that the UPR induced by mifepristone is medi-
ated by an early surge in the rate of protein synthesis as a
consequence of the increased availability of translation initi-
ator factor eIF2a. We also show for the first time thatmifepris-
tone increases autophagic flux. Lastly, we demonstrate that
blocking the UPS or the autophagy pathway in combination
with mifepristone leads to cell death. The translational value
of this study is that using mifepristone in combination with
drug/s that dysregulate the protein quality control machinery
of the cell, may cause sufficient cellular stress to tip cell fate
toward proteotoxic cell death in otherwise non-dividing
ovarian cancer cells (Figure 10). The clinical relevance of this
approach is that it can be used as a consolidation therapy
for ovarian cancer patients while in remission, followingifepristone (MF) (B) is potentiated by either proteasome inhibition (C)
D: ER associated degradation; UPR: unfolded protein response; UPS:
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 0 9 9e1 1 1 71114frontline chemotherapy aiming to delay or to prevent
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